Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Dose Topical Administration of PF-07905428 in Healthy Participants and Participants With Acne Vulgaris, and Additionally Clinical Effect in Participants With Moderate to Severe Acne Vulgaris Aged 18 to 40 Years Old

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Dose Topical Administration of PF-07905428 in Healthy Participants and Participants With Acne Vulgaris, and Additionally Clinical Effect in Participants With Moderate to Severe Acne Vulgaris Aged 18 to 40 Years Old

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 07905428 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Sponsors Pfizer

Most Recent Events

  • 30 Dec 2025 Actual primary completion date is 4 Dec 2025.
  • 30 Dec 2025 Status changed from recruiting to completed.
  • 18 Nov 2025 Planned End Date changed from 21 Nov 2025 to 4 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top